Kevin Koch Insider Profile
4 Followers
Kevin Koch, President & CEO, Director at Edgewise Therapeutics, holds 52.49K shares in Edgewise Therapeutics (Ticker: EWTX), holds 927.16K shares in Array Biopharma (Ticker: ~ARRY), holds ― shares in Viridian Therapeutics (Ticker: VRDN).
Kevin Koch has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Kevin Koch holds in companies
Most Profitable Insider Trade
Stock:
Array Biopharma
(~ARRY)
(~ARRY)
Rating:Informative Buy
Date:Nov 13, 2009 - Nov 13, 2010
Return:+59.40%
The most profitable trade made by Kevin Koch
Kevin Koch's Trading History
Edgewise Therapeutics
Aug 14, 2026
President & CEO, Director
Uninformative Buy
952.79K
$2.33M
Array Biopharma
Jul 25, 2013
―
Uninformative Sell
75.06K
$44.36M
Viridian Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Kevin Koch's performance on stock
You May Also Like
Kevin Koch insider profile FAQ
What is the percentage of profitable transactions made by Kevin Koch?
The percentage of profitable transactions made by Kevin Koch is ―.
What is the average return per transaction made by Kevin Koch?
The average return per transaction made by Kevin Koch is ―.
What stocks does Kevin Koch hold?
Kevin Koch holds: EWTX, ~ARRY, VRDN stocks.
What was Kevin Koch’s latest transaction?
Kevin Koch latest transaction was an Uninformative Buy of $952.79K.
What was Kevin Koch's most profitable transaction?
Kevin Koch’s most profitable transaction was an Informative Buy of ~ARRY stock on November 13, 2009. The return on the trade was 59.40%.
What is Kevin Koch's role in Edgewise Therapeutics?
Kevin Koch's role in Edgewise Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.